Eagle Pharmaceuticals’ Ryanodex (dantrolene sodium) Receives the US FDA’s ODD for the Treatment of Organophosphate Exposure

 Eagle Pharmaceuticals’ Ryanodex (dantrolene sodium) Receives the US FDA’s ODD for the Treatment of Organophosphate Exposure

Eagle Pharmaceuticals’ Ryanodex (dantrolene sodium) Receives the US FDA’s ODD for the Treatment of Organophosphate Exposure

Shots:

  • The US FDA has granted ODD to Eagle’s Ryanodex (dantrolene sodium) as it has the potential to treat brain damage secondary to nerve agent exposure and can protect military personnel and civilians in nerve agent attacks
  • The ODD is granted to novel drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases affecting people less than 200,000 in the US
  • If approved, Ryanodex will be the first therapy to treat brain damage secondary to nerve agent exposure

Click here ­to­ read full press release/ article | Ref: Eagle | Image: LinkedIn

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post